SCHEMBL2835560

SCHEMBL2835560

COc1cc(C)c(S(=O)(=O)N2CCC[C@H]2COc2nccc(N3CCC4(CCN(Cc5ccccc5)C4)C3)n2)c(C)c1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CASP3 P42574 11/20 0.39
CASP7 P55210 7/20 0.39
CYP3A4 P08684 4/20 0.38
CYP2D6 P10635 4/20 0.38
TSHR P16473 3/20 0.38
CYP1A2 P05177 2/20 0.38
ALDH1A1 P00352 1/20 0.38
HPGD P15428 1/20 0.38
GHSR Q92847 1/20 0.38
CASP2 P42575 2/20 0.37
CASP9 P55211 2/20 0.37
USP2 O75604 1/20 0.37
MCHR1 Q99705 1/20 0.36
CASP1 P29466 2/20 0.36
CASP6 P55212 2/20 0.36
CASP4 P49662 1/20 0.36
CASP8 Q14790 1/20 0.36
AKT1 P31749 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2836153 0.98 CYP2D6 (0.38) CASP3CASP7CYP3A4CYP2D6TSHR
SCHEMBL2835304 0.88 CASP3 (0.39) CASP3CASP7CYP3A4CYP2D6TSHR
SCHEMBL2835785 0.86 CYP2D6 (0.37) CASP3CASP7CYP3A4CYP2D6TSHR
SCHEMBL2834128 0.86 HCRTR2 (0.41) CASP3CASP7CASP2CASP9CASP1
SCHEMBL2832199 0.84 HCRTR2 (0.40) CASP3CASP7CASP2CASP9CASP1
SCHEMBL2835570 0.83 CASP3 (0.41) CASP3CASP7CYP3A4CYP2D6TSHR
SCHEMBL2832118 0.82 CASP3 (0.38) CASP3CASP7ALDH1A1CASP2CASP9
SCHEMBL2835631 0.81 PDE10A (0.37) CASP3CASP7ALDH1A1CASP2CASP9
SCHEMBL2832054 0.81 KDM4E (0.37) CASP3CASP7ALDH1A1CASP2CASP9
SCHEMBL2833717 0.81 CASP3 (0.37) CASP3CASP7ALDH1A1CASP2CASP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2356101-B1 PYRIMIDINE- AND TRIAZINE-SULFONAMIDE DERIVATIVES AS BRADYKININ B1 RECEPTOR (B1R) INHIBITORS FOR THE TREATMENT OF PAIN GRUENENTHAL GMBH (DE) 2013-02-27 EP claimed
US-8269000-B2 Substituted pyrimidine and triazine compounds GRUENENTHAL GMBH (DE) 2012-09-18 US claimed
US-20100173889-A1 Substituted Pyrimidine and Triazine Compounds GRUENENTHAL GMBH (DE) 2010-07-08 US claimed
US-8269000-B2 Substituted pyrimidine and triazine compounds GRUENENTHAL GMBH (DE) 2012-09-18 US disclosed
US-20100173889-A1 Substituted Pyrimidine and Triazine Compounds GRUENENTHAL GMBH (DE) 2010-07-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100173889-A1 Substituted Pyrimidine and Triazine Compounds ADORA2B, CCNB1, TYMS CASP3 1252/4885CASP7 1641/4885CYP3A4 1682/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.